For example, because CAFs and the ECM they produce are suggested to provide “safe havens” for cancer cells, judicious use of an HDAC inhibitor that selectively blocks ECM, without stimulating tumour-supportive cytokine expression, might prove beneficial when combined with immunotherapy, chemotherapy, or other targeted kinase inhibitors.5,39. The gene discussed is HDAC9; the disease is cancer.